News Archive
2021
Comparative Study on HTA in England, France and Germany
Short Communication paper on "Health technology assessment (HTA) in England, France and Germany: What do matched drug pairs tell us about recommendations by national HTA agencies?" in the Journal of Comparative Effectiveness Research (online available as of September 2021).
How Much Does It Cost to Research and Develop a New Drug?
Recently published systematic review and assessment in the well-known journal of PharmacoEconomics - evaluating the range and suitability of published R&D cost estimates as to the degree to which they represent the actual costs of industry (online available as of August 2021).
Report on Orphan Medicine Incentives in Europe
The European Expert Group on Orphan Drug Incentives (OD Expert Group) published a report with a set of policy proposals that will improve the OMP (Orphan Medicinal Product) incentive framework while reflecting the different stakeholder perspectives (Copenhagen Economics, May 2021).
Virtual ISPOR Europe 2020
A panel session on the topic "Social Cost Value Analysis: Do we need an alternative health economic evaluation paradigm?" was organized and moderated by Michael Schlander and, furthermore, current research projects (e.g. a multivariate analysis on health technology assessments (HTAs) published by NICE in England and GBA/IQWiG in Germany) were presented online at the Virtual ISPOR Europe 2020 (November 16-19, 2020).